Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs.

[1] It acts against interleukin 31 (IL-31),[2] which is a cytokine involved in causing itchiness (pruritus).

[2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.

[4] Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.

[4] Immune activation: Dostarlimab Other: Ibalizumab This dermatologic drug article is a stub.